These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 26856942)
21. [The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis]. Kotov SV; Fedorova SI; Iakushina TI; Lizhdvoĭ VIu Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):74-8. PubMed ID: 23528598 [TBL] [Abstract][Full Text] [Related]
22. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. Gold R; Comi G; Palace J; Siever A; Gottschalk R; Bijarnia M; von Rosenstiel P; Tomic D; Kappos L; J Neurol; 2014 Feb; 261(2):267-76. PubMed ID: 24221641 [TBL] [Abstract][Full Text] [Related]
23. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. Montgomery SM; Maruszczak MJ; Slater D; Kusel J; Nicholas R; Adlard N J Med Econ; 2017 May; 20(5):474-482. PubMed ID: 28008769 [TBL] [Abstract][Full Text] [Related]
24. Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports. Kum YE; Pamukçu Ö; Canpolat M Cardiol Young; 2023 Nov; 33(11):2384-2386. PubMed ID: 37170775 [TBL] [Abstract][Full Text] [Related]
25. Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study. Linker RA; Wendt G Neurol Ther; 2016 Dec; 5(2):193-201. PubMed ID: 27624575 [TBL] [Abstract][Full Text] [Related]
26. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy. Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552 [TBL] [Abstract][Full Text] [Related]
27. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis. Christopher KL; Elner VM; Demirci H Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512 [TBL] [Abstract][Full Text] [Related]
28. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings. Chong I; Wang KY; Lincoln CM Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079 [TBL] [Abstract][Full Text] [Related]
30. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis. Samaraweera AP; Cohen SN; Akay EM; Evangelou N Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664 [TBL] [Abstract][Full Text] [Related]
31. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients. Hovi A; Airas L J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874 [No Abstract] [Full Text] [Related]